<?xml version='1.0' encoding='utf-8'?>
<document id="28066147"><sentence text="Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin."><entity charOffset="153-161" id="DDI-PubMed.28066147.s1.e0" text="caffeine" /><entity charOffset="166-179" id="DDI-PubMed.28066147.s1.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.28066147.s1.e0" e2="DDI-PubMed.28066147.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28066147.s1.e0" e2="DDI-PubMed.28066147.s1.e1" /></sentence><sentence text="Over the last decade, physiologically based pharmacokinetics (PBPK) application has been extended significantly not only to predicting preclinical/human PK but also to evaluating the drug-drug interaction (DDI) liability at the drug discovery or development stage" /><sentence text=" Herein, we describe a case study to illustrate the use of PBPK approach in predicting human PK as well as DDI using in silico, in vivo and in vitro derived parameters" /><sentence text=" This case was composed of five steps such as: simulation, verification, understanding of parameter sensitivity, optimization of the parameter and final evaluation" /><sentence text=" Caffeine and ciprofloxacin were used as tool compounds to demonstrate the &quot;fit for purpose&quot; application of PBPK modeling and simulation for this study"><entity charOffset="1-9" id="DDI-PubMed.28066147.s5.e0" text="Caffeine" /><entity charOffset="14-27" id="DDI-PubMed.28066147.s5.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.28066147.s5.e0" e2="DDI-PubMed.28066147.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28066147.s5.e0" e2="DDI-PubMed.28066147.s5.e1" /></sentence><sentence text=" Compared to caffeine, the PBPK modeling for ciprofloxacin was challenging due to several factors including solubility, permeability, clearance and tissue distribution etc"><entity charOffset="13-21" id="DDI-PubMed.28066147.s6.e0" text="caffeine" /><entity charOffset="45-58" id="DDI-PubMed.28066147.s6.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.28066147.s6.e0" e2="DDI-PubMed.28066147.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28066147.s6.e0" e2="DDI-PubMed.28066147.s6.e1" /></sentence><sentence text=" Therefore, intensive parameter sensitivity analysis (PSA) was conducted to optimize the PBPK model for ciprofloxacin"><entity charOffset="104-117" id="DDI-PubMed.28066147.s7.e0" text="ciprofloxacin" /></sentence><sentence text=" Overall, the increase in Cmax of caffeine by ciprofloxacin was not significant"><entity charOffset="34-42" id="DDI-PubMed.28066147.s8.e0" text="caffeine" /><entity charOffset="46-59" id="DDI-PubMed.28066147.s8.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.28066147.s8.e0" e2="DDI-PubMed.28066147.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28066147.s8.e0" e2="DDI-PubMed.28066147.s8.e1" /></sentence><sentence text=" However, the increase in AUC was observed and was proportional to the administered dose of ciprofloxacin"><entity charOffset="92-105" id="DDI-PubMed.28066147.s9.e0" text="ciprofloxacin" /></sentence><sentence text=" The predicted DDI and PK results were comparable to observed clinical data published in the literatures" /><sentence text=" This approach would be helpful in identifying potential key factors that could lead to significant impact on PBPK modeling and simulation for challenging compounds" /><sentence text="" /></document>